Php275 - Orphan Medicinal Products Given an Initial Negative Recommendation by Nice's Sta Process but Approved Following Re-Evaluation in England

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1169
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Psy60 - Orphan Versus Ultra-Orphan Drugs Prices in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Patient-Reported Outcomes in Orphan Drug Labels Approved by the US FDA

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Analysis of the Ultra-Orphan Drugs Approved by the Fda in the Period 1983-2014

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Pivotal Studies of Orphan Drugs Approved for Neurological Diseases

Annals of Neurology
Neurology
2009English

Psy176 - Significant Benefit and Relative Effectiveness Assessment of Orphan Medicinal Products in the European Union: A Comparative Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Unexpected Re-Emergence of Clinical Allergy Following Negative Oral Food Challenges

Journal of Allergy and Clinical Immunology
AllergyImmunology
2017English

Pro Labeling in Products Approved by the European Medicines Agency (EMA) for Narcolepsy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

A National Pulmonary Hypertension Service for England & Wales: An Orphan Disease Is Adopted?

Thorax
PulmonaryRespiratory Medicine
2002English

Marine Natural Products in Medicinal Chemistry

ACS Medicinal Chemistry Letters
Organic ChemistryBiochemistryDrug Discovery
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy